# Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

> **NCT05100160** · PHASE3 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Thoracic
- Pulmonary Disease

## Interventions

- **DRUG:** Gabapentin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05100160
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-09-15
- **Primary completion:** 2023-01-03
- **Final completion:** 2023-01-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** 0 patient accrual
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100160, "Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05100160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*